The canonical profile remains the primary reading view. Read the canonical profile.
We added a plain-language reader guide with cited answers, re-checked the Gvoke and Gvoke VialDx label, and added Drugs@FDA approval records for glucagon products. 125
What this version reported
Smaller controlled crossover studies described in the label found that nearly all participants reached the target rise in blood sugar within 30 minutes. The label keeps the severe-hypoglycemia and diagnostic uses separate.↗
Reader guide in this version
Key takeaway
Glucagon is a natural hormone made by the pancreas that raises blood sugar by releasing glucose stored in the liver.1 It has been FDA-approved since 1960. The label cited here covers two uses that must not be confused: Gvoke to treat severe low blood sugar in people with diabetes aged 2 and older, and Gvoke VialDx as a diagnostic aid that briefly stops gut movement during X-ray examinations in adults.1,2 Its approval for severe low blood sugar rests on smaller controlled crossover studies in which nearly all participants’ blood sugar rose to the target within 30 minutes.1
At a glance
- What it is
- A peptide hormone. The label states that glucagon raises blood sugar by activating glucagon receptors in the liver, which releases stored glucose.1
- FDA status
- FDA-approved. Drugs@FDA lists the first glucagon application with an approval date of November 14, 1960, and Gvoke with an approval date of September 10, 2019. The cited label has no boxed warning.1,2,5
- Human evidence
- Two randomized crossover studies in 80 and 81 adults with type 1 diabetes and a study in 31 children, described in the label.1
- Evidence strength
- Smaller controlled human trials
What is glucagon?
Glucagon is a peptide hormone that the body makes in the pancreas. Lab-made glucagon is used as a medicine.1
Drugs@FDA lists several glucagon applications, including Eli Lilly’s original application approved in 1960, Fresenius Kabi’s glucagon, Baqsimi and Gvoke.2,3,4,5
How does glucagon work?
The label states that glucagon raises blood sugar by activating glucagon receptors in the liver, which breaks down stored glycogen and releases glucose. It needs liver glycogen stores to work.1
The label also states that glucagon relaxes the smooth muscle of the stomach and intestines, which is the basis of its diagnostic use.1
What do human studies show?
The label describes two multicenter crossover studies in adults aged 18 to 74 with type 1 diabetes, with 80 and 81 participants, in which blood sugar was lowered with insulin and each participant received Gvoke and another glucagon product at separate visits.1
Treatment success, defined as a predefined rise in blood sugar within 30 minutes, occurred in 98.7% of the Gvoke group and 100% of the comparison group, meeting the studies’ non-inferiority margin, according to the label.1
In a study of 31 children with type 1 diabetes, all 30 evaluable children reached the target rise in blood sugar, according to the label.1
What the evidence base contains
- Controlled human trial Two multicenter randomized crossover studies in adults with type 1 diabetes (80 and 81 participants) that compared Gvoke with another glucagon product after blood sugar was lowered with insulin.1
- Small, short, or incompletely reported human study A study in 31 children with type 1 diabetes, all evaluable participants of whom reached the target rise in blood sugar.1
Evidence-strength label: Smaller controlled human trials. How this label is assigned
Is glucagon FDA-approved?
Yes. Drugs@FDA lists Eli Lilly’s glucagon application with an approval date of November 14, 1960, Baqsimi with an approval date of July 24, 2019, and Gvoke with an approval date of September 10, 2019.2,4,5
The Gvoke and Gvoke VialDx label cited here (DailyMed SPL version 2, published July 9, 2026) states that Gvoke is indicated for severe hypoglycemia in adults and children aged 2 and older with diabetes, and that Gvoke VialDx is indicated as a diagnostic aid during radiologic examinations to temporarily stop movement of the gastrointestinal tract in adults.1
The label has no boxed warning. It states that glucagon is contraindicated in people with pheochromocytoma, insulinoma or a prior allergic reaction to it, and that diagnostic use is also contraindicated in people with glucagonoma.1
Its warnings cover a large rise in blood pressure with pheochromocytoma, low blood sugar with insulinoma or glucagonoma, serious allergic reactions, lack of effect when liver glycogen is depleted, a skin rash called necrolytic migratory erythema, and, for diagnostic use, high blood sugar in people with diabetes and increases in blood pressure and heart rate in people with heart disease.1
Timeline
- FDA approves Eli Lilly’s glucagon application, according to Drugs@FDA.2
- FDA approves Fresenius Kabi’s glucagon application, according to Drugs@FDA.3
- FDA approves Baqsimi, according to Drugs@FDA.4
- FDA approves Gvoke, according to Drugs@FDA.5
- DailyMed publishes the Gvoke and Gvoke VialDx label version cited on this page.1
What is still unknown?
How well it works when liver glycogen is low, for example during starvation or long-lasting low blood sugar: the label warns that it may not be effective then.1
How other glucagon products compare: this page cites one label covering Gvoke and Gvoke VialDx, and other glucagon products have their own labels.1,3,4
Sources for this version
- 1GVOKE VIALDX (glucagon) injection, solution · SPL version 2 · published 2026-07-09 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026
- 2Drugs@FDA application NDA012122 · original submission status AP · 1960-11-14 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 3Drugs@FDA application NDA201849 · original submission status AP · 2015-05-08 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 4Drugs@FDA application NDA210134 · original submission status AP · 2019-07-24 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 5Drugs@FDA application NDA212097 · original submission status AP · 2019-09-10 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026